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Abstract
Background: Small cell carcinoma of the bladder (SCCB) is a kind of rare and highly aggressive tumor that is present
in an advanced stage and has a propensity for early metastasis. The main presenting symptom of SCCB is hematuria.
Surgery, chemotherapy, and radiotherapy, either alone or as a part of combined therapy, have been used as the
treatment. The aim of this study is to present our experience with 9 SCCB patients who were treated with different
modalities and to share the findings upon reviewing the literatures for patients with SCCB reported in 56 literatures in
Chinese.
Methods: We retrospectively evaluated 9 patients with SCCB from February 1980 to January 2014 in Tongji Hospital,
Huazhong University of Science and Technology. The general characteristics, clinical manifestations, the pathological
and immunohistochemical characteristics, treatment options, and prognostication in those eligible manuscripts were
analyzed. In order to gain a better understanding of the clinical features of SCCB, another 119 cases reported in 56
articles were reviewed together (from January 1979 to March 2014). And a retrospective analysis was performed.
Results: All the 9 cases in Tongji Hospital were successfully operated, and the tissue samples were sent for pathological
examination. All the tumor tissues contained small cell carcinoma components. 4 cases coexisted with other histologic
types of bladder cancers, and 2 out of the 9 cases had three different cell components. All the patients had muscle
invasion, and 4 cases showed lymph nodes metastasis, 3 cases showed invasion of neighboring structures (seminal
vesicle or uterus), and 1 case was highly suspected of liver metastasis. Immunohistochemistry results showed that PCK,
Syn, NSE, and CD56 were all positive, but LCA was negative. After operations, 3 patients underwent chemotherapy and
only 1 patient received postoperative radiotherapy. Patients were followed up, ranging from 3 to 84 months and the
median survival time was 33 months. The leading cause of death was tumor recurrence or metastasis, while 2 patients
are still alive. According to the published literature, the pathological stage, immunohistochemical markers, and survival
curves of all the 128 cases were also retrospectively analyzed.
Conclusions: SCCB is different from transitional cell carcinoma (TCC) of the bladder. It has its unique cytology,
immunohistochemistry, and ultrastructural features. Its diagnosis relies on pathological examination and
immunohistochemistry. The current main treatment for SCCB is surgery combined with chemotherapy. Since the
disease develops early metastasis easily, the overall prognosis of this cancer is poor. Further research need to
clarify the molecular pathogenesis so that novel therapies can be developed for this rare cancer.
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Background
Small cell carcinoma (SCC) is one subtype of the
histopathological classifications with invasive bio-
logical behavior. It was mostly found in lung cancer.
Small cell carcinoma outside the lungs only accounted
for 4% of all small cell carcinomas. Small cell carcin-
oma of the bladder (SCCB) is very rare. Since first re-
ported in 1981, its incidence accounts for about 0.5 ~
1% of primary bladder tumor; there has been about
1000 cases reported so far [1]. The definite etiology
and pathogenesis are not clear yet. Clinical treatments
of SCCB have neither consistent correlation scheme
nor a randomized clinical trial. Therapy modes in-
clude surgery, chemotherapy, and radiotherapy. Be-
cause of the rarity of this tumor, no prospective trials
have been done to evaluate the optimal treatments
[2]. The aim of the present study was to describe the
clinical pathological features and outcomes of the




For this retrospective, observational study, the med-
ical records data of the nine SCCB patients were
obtained from Tongji Hospital, Huazhong University
of Science and Technology from February 1980 to
January 2014. The first case was diagnosed in March
1980 and the last in October 2013. Follow-up ended
in January 2014. Clinical and demographic informa-
tion obtained through the hospital records included
clinical manifestations and follow-up. The general
characteristics, clinical manifestations, the pathological
and immunohistochemical characteristics, treatment
options, and prognostication of the nine SCCB cases
were analyzed. Statistical analysis was performed
using commercially available software. Kaplan-Meier
survival curves were calculated. This study was ap-
proved by the Ethics Committee of Tongji Hospital,
Tongji Medical College, Huazhong University of
Science and Technology.
Table 1 Characters of SCCB in 9 cases in Tongji Hospital
Case Sex Age Size of tumor (cm) Sites Syndromes Imaging features Pathology, stage
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Literature review
In order to gain a better understanding of the clinical
features of SCCB, another 119 cases reported in 56 arti-
cles (from January 1979 to March 2014) were reviewed
together with the 9 cases in Tongji Hospital, Huazhong
University of Science and Technology. A retrospective
analysis of all the 128 SCCB cases was performed. The
pathological stage, immunohistochemical markers, and
survival curves of all the 128 cases were also retrospectively
analyzed. Kaplan-Meier survival curves were calculated.
Results
Clinicopathological features
We investigated the 9 cases including 7 males and 2
females. Their ages were between 43 and 68 years old
and 56 in averages. Lesions were found in the lateral wall
of bladder in 7 cases, posterior wall in 2 cases, including
1 case of multiple. The sizes of tumor ranged between
1.5 cm × 2.0 cm and 6.2 cm × 5.0 cm. Intermittent pain-
less gross hematuria were presented in all the patients
and accompanied bywaist pain in 2 cases. Five male cases
had smoking history. Physical examanation found that
bilateral renal percussive pain is positive in 2 cases, left
renal percussive pain is positive in 1 case, and deep ten-
derness of bladder in 1 case. All cases were scanned by
ultrasound or CT. Enlargement of lymph nodes were
found in 6 cases, seminal vesicle invasion in 2 cases, and
rectum or uterus invasion in 3 cases. First time path-
ology or biopsy found transitional cell carcinoma in 5
cases, 1 case of highly differentiated adenocarcinoma, 1
case of glandular cystitis, and 1 case of inverted papil-
loma (Table 1).
After definite diagnosis, 9 cases were treated with corre-
sponding surgery according to different conditions and
stages of tumors (Table 2). Postoperative pathology showed
different histopathological conclusions (Table 3) (Fig. 1).
When recovered from operation, 4 cases were treated with
chemotherapy and only 1 case was with radiotherapy. Four
cases received partial cystectomy. After at least 6-
month follow-up, Kaplan-Meier survival curves for 9 cases
showed survival rates (Fig. 2). According to published re-
ports in China, we analyzed outcomes of different
surgeries for the 128 SCCB patients (Fig. 3).
We also analyzed pathological types of 128 patients, in
which 51/128 (39.8%) were isolated small cell carcinoma,
and 72/128 (56.3%) were mixed small cell carcinoma. In
all cases, tumors in 53/72 cases were combined with
transitional cell carcinoma (73.6%), 8/72 with squamous
cell carcinomas (11.1%), 5/72 with adenocarcinoma
(6.9%), 4/72 with carcinoma in situ (5.6%), 3/72 with
three kinds of cells composition (4.2%) (Fig. 4). Even in
2 cases, the tumors were composited of four kinds of
cells including transitional cell carcinoma of bladder,
small cell carcinoma, squamous carcinoma, and adeno-
carcinoma. SCCB is featured with various epithelial or
nerve secretory symbols. One hundred and three out of
128 cases express one or more neuroendocrine markers
such as NSE, CgA, and Syn. NSE is the most
Table 2 Histopathological feature of SCCB in 9 cases
NSE PCK Syn CD56 CgA LCA EMA Ki-67Li
1 + + + + + − + −
2 + + + + − − + −
3 + + + + − − − −
4 + +− + + − − + 99%
5 + + +− + − − + −
6 + + + + + − − −
7 + +− + + + − − 60%
8 + + + + + + − 90%
9 + + +− + + − + 60%
NSE neuron specific enolase, PCK broad-spectrum cytokines, Syn synaptophysin,
CgA addicted chromogranin A, LCA leukocyte common antigen, EMA epithelial
membrane antigen, Ki67 status labeled antigen
Table 3 Treatment characteristics and follow-up
1 2 3 4 5 6 7 8 9
PRB √ √ √ √
TRB √ √ √ √
LND √ √ √ √
RBI √ √ √ √
SCS √
BI √ √ √ √
CT √ √ √ √
RT √
















PRB partial resection of bladder, TRB total resection of bladder, LND Lymph node dissection, RBI reconstruction of bladder with intestinal tract, CS skin colostomy
surgery, BI bladder irrigation, CT chemotherapy, RT radiotherapy, TTL time to live, PG prognosis
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sensitive marker and its positive rate is 73.4%. EMA has
the highest positive rate among epithelial symbols
(62.5%) and followed by keratin (61%), CEA (50%), and
Leu-M1 (43.8%) (Fig. 5). Kaplan-Meier survival curves
showed the outcomes between pure small cell type and
mixed cell type of SCCB are different (Fig. 6).
Many studies suggest that NSE, CgA, Syn, and etc. play
important roles in SCCB diagnosis. Epithelial membrane
antigen has no specificity, but important in differential
diagnosis. For example, LCA is positive in lymphoma but
not expressed in SCCB. Despite of a variety of treatments,
SCCB has poor overall prognosis for fast growth, strong
invasion, and early metastasis (Fig. 7).
Discussion
We analyzed retrospectively nine cases with SCCB
diagnosed between 1980 and 2014. Combined with
published reports, we investigated clinical symptoms,
histopathological characters, treatments, and prognosis
to enhance the understanding of SCCB.
Incidence of bladder cancer accounted for 5% of malig-
nant tumor, and it is the second most common urologic
malignancy. Up to 95% bladder cancer are of epithelial ori-
gin, among which 90% are urothelial neoplasms and
followed by squamous cell carcinoma (5–8%) and adeno-
carcinoma (1–2%) [3]. Non-epithelial tumors are rare, such
as small cell carcinoma and sarcoma. SCCB is a highly ma-
lignant tumor that occurs mainly in lung and esophagus.
Extra-pulmonary small cell carcinoma accounted for 4% of
all small cell carcinoma [4]. The disease was firstly de-
scribed in 1981 by Cramer, and its incidence accounted for
0.5–1% of primary bladder tumors. About 50% SCCB are
compound bladder cancers that combined with other
histological bladder tumors. Average age of incidence is
about 66.9 years old and 79% patients have a history of
smoking. Males have three to five times incidence higher
than female. So smoking may be one of the causes of the
illness. Other environmental and individual risk factors are
not confirmed as the etiology, but the underlying factors
include chronic cystitis, bladder stones and cystoplasty [5].
Up to now, pathogenesis of SCCB is not clear. Similar to
lung small cell cancer, SCCB may be associated with
chromosomal aberrations, such as certain sites lacking
tumor suppressor genes or chromosomes areas containing
cancer-causing genes (such as c-MYC) abnormal amplifica-
tion. Silence of the tumor or metastasis suppressor gene is
considered to be another potential mechanism of bladder
cancer [6].
Histopathological forms of SCCB have no obvious
difference with general bladder tumors. It belongs to a
part of neuroendocrine tumor group. Characteristically,
small amounts of neurosecretory granules in 150 ~
250 nm diameter can be found under the electron
microscope. About 50% SCCB contains the other kinds
of cancer, such as transitional cell carcinoma, adenocar-
cinoma, and squamous carcinoma. It can also be associ-
ated with transitional epithelial atypical hyperplasia or
carcinoma in situ. The possible reason is that SCCB is
derived from the neural crest of submucosa all-around
poorly differentiated stem cell population [7]. SCCB
diagnosis mainly depends on cystoscopic biopsy lesions
and postoperative histopathological examination, such as
measurements by light microscopy cell morphology, cell
ultrastructure electron microscope examination, and
immunohistochemical examination. Preoperative ex-
aminations also include imaging, such as CT or MRI
scan, urine cytology, cystoscopy, and biopsy. Cytology of
SCCB is similar with poorly differentiated squamous cell
carcinoma, adenocarcinoma, and transitional cell carcin-
oma, so diagnostic identification relies on electron micros-
copy or immunohistochemistry [8]. Eight cases in our
report were mistaken as transitional cell carcinoma,
inverted papilloma, and glandular cystitis et al. before di-
agnosed. Since there are clear distinctions in treatment
programs between SCCB and other bladder tumors, we
Fig. 1 Immunohistochemical staining shows expression of different cell markers
Fig. 2 Kaplan-Meier survival curves for 9 cases
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should raise awareness of the disease and carefully check
the tissue samples in order to avoid misdiagnosis, missed
diagnosis, and delay of treatment timing.
Since SCCB is clinically rare tumor, there is no stand-
ard treatment. In absence of multi-center randomized
study, most treatments are multi-mode combination
therapy based on single-center retrospective study, so
that its variability in treatment programs is great. Most
scholars believe that SCCB is a mixed cell carcinoma
and advocate the preferred surgical treatment, including
radical cystectomy, partial cystectomy, or transurethral
resection of bladder tumors (TURBT). Parts of scholars
believe that the majority of SCCB has occurred micro-
metastases locally at the time of diagnosis. Therefore,
surgery alone is not enough and the combination of
radiotherapy and chemotherapy is needed [9]. In our an-
alyzed group, 102 patients were treated with surgery in
128 cases (79.7%), in which TURBT, partial resection
and radical resection account for 41/102 (40.2%),
15/102 (14.7%), and 46/102 (45.1%), respectively. We
recommend surgery as the priority. Chemotherapy plays
a prominent role in the management of SCCB. Bladder
cancer cells are sensitive to chemotherapy, especially
transitional cell cancer, but partial bladder infusion
chemotherapy cannot effectively prevent cancer metasta-
sis. Systemic chemotherapy based on platinum was pre-
viously advocated for SCCB treatment. Mackey
retrospectively analyzed 106 cases of SCCB. He believed
that cisplatin-based chemotherapy was an independent
prognostic factor and should be used in the treatment
[10]. Choong thought that chemotherapy should be used
on III and IV periods and not recommended for II
period [11]. Abbas analyzed retrospectively that the
average survival time of radical cystectomy surgery com-
bined with chemotherapy was 21 months [12]. Siefker
reported that neoadjuvant chemotherapy could reduce
preoperative staging and was beneficial for surgical
removal to prolong survival time of patients [13]. Eto-
poside, cisplatin, and carboplatin are usually used for
pure SCCB and methotrexate, vincristine, adriamycin,
Fig. 3 Kaplan-Meier survival curves of outcomes of difference surgeries for the 128 SCCB patients. The radical cystectomy group survival rates of
1, 2, 3 years are 68.11, 46.31, 22.05%, respectively. The non-cystectomy group survival rates of 1, 2, 3 years are 49.36, 29.24, 8.03%, respectively. The
mean survival time of the two groups was 23.86 and 17.77 months, respectively. There was no statistically difference between the two groups
(Log-rank test, X2 = 2.6041, P = 0.1066)
Fig. 4 Pathological stage ratio of 128 cases Fig. 5 Features of immunohistochemical markers of SCCB in 128 cases
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cyclophosphamide, etoposide, or cisplatin for SCCB
combined with transitional cell carcinoma. In our
study, chemotherapy (local + systemic) and radiation ther-
apy respectively account for 48.5% and 34.6% of 128 cases.
Lack of unified chemotherapy treatments, chemotherapy
drugs cannot be comparable. For SCCB with skull or bone
metastasis, radiation therapy may be recommended. In
addition, local chemotherapy via internal iliac catheter can
be applied for patients with poor physical fitness or unre-
sectable primary tumors.
Distant metastasis occurs in 78% of patients. The pa-
tients with treatments had a better median survival of 12
to 24 months compared to the patients without treat-
ments of 4 to 5 months. Trials reported that 2-, 3-, and 5-
year survival rates of SCCB were 20, 13, and 8%, respect-
ively [14]. Choong et al. studied retrospectively that 1-, 3-,
and 5-year survival rates of 44 cases of SCCB were 61.4,
27.3, and 25%. In our study, the average survival time was
20.54 months; 1-, 2-, 3-, and 4-year survival rates were
57.78, 36.94, 16.61, and 2.97%, respectively.
Conclusions
SCCB is a malignant tumor with lower degree differenti-
ation and a highly invasion and metastasis. It is clinically
rare. Majority of patients with SCCB have hematuria
symptoms. When diagnosed, it is often already ad-
vanced so that the prognosis is poor. SCCB has unique
biological characteristics with positive neuroendocrine
markers. The most sensitive marker is NSE that has
well specification. Hence, diagnosis of SCCB depends
on pathology and immunohistochemistry. Radical
bladder cystectomy combined with chemotherapy or
radiotherapy can improve survival time. The out-
comes of different cell types of SCCB are different.
Surgery is still the main treatment of SCCB, but
multi-mode integrated treatment should be a better
alternative. Treatment schedules of SCCB refer to the
current small cell lung cancer principles. It is difficult
to determine the best options through prospective
studies. Early detection, diagnosis, and treatment are
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